Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.04%
median of 850 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$259.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$258.00M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$257.94M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$260.79M
Net Profit Margin
-568.80%
TTM Avg
-845.08%
3Y Avg
-422.54%
5Y Avg
-626.87%
Market Cap
$262.11M
Net Profit Margin
-6388.20%
TTM Avg
0.00%
3Y Avg
-1230.00%
5Y Avg
-820.00%
Market Cap
$255.95M
Net Profit Margin
-3.14%
TTM Avg
-28.33%
3Y Avg
-34.54%
5Y Avg
-25.62%
Market Cap
$262.66M
Net Profit Margin
-43.70%
TTM Avg
-35.13%
3Y Avg
-15.36%
5Y Avg
-13.33%
Market Cap
$262.92M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$263.68M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $259.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| AC Immune S.A. (ACIU)vs › | $258.00M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $257.94M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $260.79M | -568.80% | -845.08% | -422.54% | -626.87% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -6388.20% | 0.00% | -1230.00% | -820.00% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.95M | -3.14% | -28.33% | -34.54% | -25.62% |
| OraSure Technologies, Inc. (OSUR)vs › | $262.66M | -43.70% | -35.13% | -15.36% | -13.33% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.92M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | -10994.73% | -520.92% | -360.66% | -288.77% |
| Scribe Therapeutics Inc. (SCTX)vs › | $265.87M | N/A | N/A | N/A | N/A |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
